Coffee and tea consumption, genotype- based CYP1A2 and NAT2 activity and colorectal cancer risk- Results from the EPIC cohort study

Coffee and tea consumption, genotype- based CYP1A2 and NAT2 activity and colorectal cancer risk- Results from the EPIC cohort study

Dik, Vincent K. Bueno-de-Mesquita, H. B(as) Van Oijen, Martijn G. H. Siersema, Peter D. Uiterwaal, Cuno S. P. M. Van Gils, Carla H. Van Duijnhoven, Fraenzel J. B. Cauchi, Stephane and Yengo, Loic Froguel, Philippe Overvad, Kim Bech, Bodil H. and Tjonneland, Anne Olsen, Anja Boutron-Ruault, Marie-Christine and Racine, Antoine Fagherazzi, Guy Kuehn, Tilman Campa, Daniele Boeing, Heiner Aleksandrova, Krasimira Trichopoulou, Antonia Peppa, Eleni Oikonomou, Eleni Palli, Domenico and Grioni, Sara Vineis, Paolo Tumino, Rosaria Panico, Salvatore and Peeters, Petra H. M. Weiderpass, Elisabete Engeset, Dagrun and Braaten, Tonje Dorronsoro, Miren Chirlaque, Maria-Dolores and Sanchez, Maria-Jose Barricarte, Aurelio Zamora-Ros, Raul and Argueelles, Marcial Jirstroem, Karin Wallstroem, Peter and Nilsson, Lena M. Ljuslinder, Ingrid Travis, Ruth C. Khaw, Kay-Tee Wareham, Nick Freisling, Heinz Licaj, Idlir and Jenab, Mazda Gunter, Marc J. Murphy, Neil Romaguera-Bosch, Dora Riboli, Elio

scientific_publication_article

Επιστημονική δημοσίευση - Άρθρο Περιοδικού (EL)

Scientific publication - Journal Article (EN)

2014

Coffee and tea contain numerous antimutagenic and antioxidant components and high levels of caffeine that may protect against colorectal cancer (CRC). We investigated the association between coffee and tea consumption and CRC risk and studied potential effect modification by CYP1A2 and NAT2 genotypes, enzymes involved in the metabolization of caffeine. Data from 477,071 participants (70.2% female) of the European Investigation into Cancer and Nutrition (EPIC) cohort study were analyzed. At baseline (1992-2000) habitual (total, caffeinated and decaffeinated) coffee and tea consumption was assessed with dietary questionnaires. Cox proportional hazards models were used to estimate adjusted hazard ratio’s (HR) and 95% confidence intervals (95% CI). Potential effect modification by genotype-based CYP1A2 and NAT2 activity was studied in a nested case-control set of 1,252 cases and 2,175 controls. After a median follow-up of 11.6 years, 4,234 participants developed CRC (mean age 64.78.3 years). Total coffee consumption (high vs. non/low) was not associated with CRC risk (HR 1.06, 95% CI 0.95-1.18) or subsite cancers, and no significant associations were found for caffeinated (HR 1.10, 95% CI 0.97-1.26) and decaffeinated coffee (HR 0.96, 95% CI 0.84-1.11) and tea (HR 0.97, 95% CI 0.86-1.09). High coffee and tea consuming subjects with slow CYP1A2 or NAT2 activity had a similar CRC risk compared to non/low coffee and tea consuming subjects with a fast CYP1A2 or NAT2 activity, which suggests that caffeine metabolism does not affect the link between coffee and tea consumption and CRC risk. This study shows that coffee and tea consumption is not likely to be associated with overall CRC. What’s new? Coffee and tea contain numerous compounds that may protect against colorectal cancer (CRC). In this study of more than 475,000 participants over more than a decade, the authors investigated whether coffee or tea consumption is associated with an altered risk of developing CRC. They also asked whether genetic variations in two enzymes involved in caffeine metabolism (CYP1A2 and NAT2) might affect this risk. They conclude that neither consumption patterns, nor genetic differences in caffeine metabolism, appear to have a significant impact on CRC risk. (EN)

Αγγλική γλώσσα

Ερευνητικό υλικό ΕΚΠΑ

https://creativecommons.org/licenses/by-nc/4.0/

Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών

Πέργαμος

Άρθρο Περιοδικού (Journal Article)